<code id='69DBE44A3C'></code><style id='69DBE44A3C'></style>
    • <acronym id='69DBE44A3C'></acronym>
      <center id='69DBE44A3C'><center id='69DBE44A3C'><tfoot id='69DBE44A3C'></tfoot></center><abbr id='69DBE44A3C'><dir id='69DBE44A3C'><tfoot id='69DBE44A3C'></tfoot><noframes id='69DBE44A3C'>

    • <optgroup id='69DBE44A3C'><strike id='69DBE44A3C'><sup id='69DBE44A3C'></sup></strike><code id='69DBE44A3C'></code></optgroup>
        1. <b id='69DBE44A3C'><label id='69DBE44A3C'><select id='69DBE44A3C'><dt id='69DBE44A3C'><span id='69DBE44A3C'></span></dt></select></label></b><u id='69DBE44A3C'></u>
          <i id='69DBE44A3C'><strike id='69DBE44A3C'><tt id='69DBE44A3C'><pre id='69DBE44A3C'></pre></tt></strike></i>

          Home / entertainment / hotspot

          hotspot


          hotspot

          author:explore    Page View:4
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In